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CObjective: The Uterine Fibroid Symptom and Quality of Life (UFS-QOL)
questionnaire, a validated patient-reported outcome measure of fibroid
symptoms and health-related quality of life, was modified for use posthys-
terectomy. This study was conducted to psychometrically validate
the UFS-QOL-Hysterectomy questionnaire for potential use in com-
parative effectiveness research to evaluate uterine fibroid treatments.
Methods: This multicenter prospective study enrolled premenopausal
women aged 30 to 50 years with uterine fibroids who were scheduled for
hysterectomy, myomectomy, or uterine fibroid embolization. All partici-
pantscompletedtheUFS-QOLquestionnaireandshortform36healthsurvey
at baseline prior to treatment and 6 and 12months postprocedure.Women
with hysterectomy completed the UFS-QOL-Hysterectomy questionnaire
during follow-up visits. Internal consistency reliability, discriminant and
concurrent validity, and responsiveness were assessed. Results: A total of
74 women were enrolled (107 uterine fibroid embolization, 61 myomec- O
rpor
al So
ttp://dx.doi.org/10.1016/j.jval.2012.03.1387omy, and 106 hysterectomy) and 89 (83%), 55 (90%), and 91 (86%), respec-
ively, completed the 12-month follow-up. The mean age was 43.2 (uterine
broid embolization), 40.6 (myomectomy), and 44.5 (hysterectomy) years;
3%, 43%, and 37%, respectively, were black. Cronbach’s alphas for the UFS-
OL-Hysterectomy questionnaire at 6months ranged from 0.70 to 0.96 and
rom0.66to0.95at12months.Effectsizesrangedfrom1.23to2.55, indicating
hat the UFS-QOL-Hysterectomy questionnaire was highly responsive.
onclusions: The UFS-QOL-Hysterectomy questionnaire is a valid and re-
iable patient-reported outcome measure of uterine fibroid treatment with
ysterectomy and can be used in conjunction with the UFS-QOL question-
aire to compare patient-reported outcomes across treatments.
eywords: patient-reported outcomes, questionnaire modification,
ymptoms, uterine fibroids.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Uterine fibroids are common [1] and cause significant morbidity.
These benign tumors of the female reproductive tract cause symp-
toms including menorrhagia, dysmenorrhea, pelvic and low back
pain, dyspareunia, and urinary urgency and frequency. The lifetime
cumulative incidence of uterine fibroids is up to 80% amongAfrican-
American and 70% among white women [2]. Treatment options for
uterine fibroids include surgical procedures of hysterectomy and
myomectomy and nonsurgical treatments of uterine fibroid emboli-
zation (UFE) andmagnetic resonance–guided focusedultrasound [3].
The relative effectiveness of UFE, hysterectomy, and myomectomy,
however, has not been studied in depth.
Comparative effectiveness research (CER) is a directive of the re-
cently enacted Patient Protection and Affordable Care Act. CER within
this legislation is defined as research evaluating and comparing the
health outcomes and clinical effectiveness, risks, andbenefits of twoor
moremedical treatments, services, or clinicalmanagement andhealth
practices [4].Thecomparativestudiesofuterinefibroid treatmentscon-
ducted to date are limited by the lack of validated, condition-specific
outcomemeasures that can compare outcomes across uterus-remov-
ing (i.e., hysterectomy) and uterus-sparing (i.e., myomectomy, UFE,
* Address correspondence to: Karin S. Coyne, United BioSource Co
E-mail: Karin.Coyne@unitedbiosource.com.
098-3015/$36.00 – see front matter Copyright © 2012, Internation
ublished by Elsevier Inc.magnetic resonance–guided focused ultrasound) treatment groups. In
previous studies of uterine fibroids, theMedical Outcomes Study short
form 36 health survey (SF-36) has been used to investigate patient-re-
portedhealthoutcomes [5–8];however, theSF-36 is limitedbecause it is
a generic health outcomemeasure andmaynot be sensitive to specific
uterine fibroid patient outcomes.
TheUterine Fibroid SymptomandQuality of Life (UFS-QOL) ques-
tionnairewascreatedandvalidated [9] tobeusedasacross-sectional
and longitudinal instrument for measuring fibroid-related symp-
toms and health-related quality of life (HRQOL) impact. Tomake the
UFS-QOL questionnaire relevant to women posthysterectomy, how-
ever, the instructions of the UFS-QOL questionnaire needed to be
slightly modified to reflect the absence of the uterus and menstrual
periods. The purpose of this study was to evaluate the internal con-
sistency reliability, validity, and responsivenessof theUFS-QOL-Hys-
terectomy questionnaire.
Materials and Methods
This multicenter comparative, prospective outcome study of
women undergoing treatment for uterine fibroids has been previ-
ously described [10]. Briefly, a convenience sample of premeno-
ation, 7101 Wisconsin Ave, Suite 600, Bethesda, MD 20814.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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willing to provide written informed consent and able to speak and
read English were recruited from three university medical centers
and one academic military medical center to participate in the
study as they were scheduled for treatment via hysterectomy,
myomectomy, or UFE.Women providedwritten informed consent
at the clinical site prior to completing any study-related proce-
dures and then completed the UFS-QOL questionnaire, SF-36, and
a brief sociodemographic questionnaire prior to their scheduled
treatment and mailed the completed questionnaire packet in a
preaddressed stamped envelope to the data center. Follow-up
questionnaire packets were mailed to each participant at 6 and 12
months postprocedure and contained an Overall Treatment Effect
scale and the UFS-QOL questionnaire (for women who had under-
gone either UFE or myomectomy) or the UFS-QOL-Hysterectomy
questionnaire (for womenwho had undergone hysterectomy), SF-
36, and several health care utilization items. Participants mailed
the completed packets to the data center in preaddressed stamped
envelopes.
Each center’s institutional review board approved the study;
the study was conducted in compliance with the Health Informa-
tion Portability and Accountability Act and the principles outlined
in the Declaration of Helsinki.
Questionnaires utilized in the study
Medical outcomes study short form 36
The SF-36 is a 36-item self-administered generic measure de-
signed to assess general health status [11]. The SF-36 is composed
of eight subscales: physical functioning, role-physical, bodily pain,
general health, vitality, social functioning, role-emotional, and
mental health, as well as two composite scores, the physical com-
ponent score and the mental component score. Individual items
from each subscale are combined to form a subscale rating and
transformed to a 0 to 100 scale. Higher scores indicate better
quality of life, and the recall period is 4 weeks. Reference values
derived in a healthy population, distributed by age and sex, are
available.
Uterine fibroid symptom and quality of life questionnaire
The UFS-QOL questionnaire was developed from focus groups of
women with uterine fibroids [9]. The final questionnaire consists
of an eight-item symptom severity scale and 29 HRQOL questions,
which comprise six subscales: concern, activities, energy/mood,
control, self-consciousness, and sexual function. Participants are
instructed to consider their experiences with uterine fibroids dur-
ing the previous 3 months. Response options for the symptom
severity subscale are on a five-point Likert-type scale and range
from “not at all” to “a very great deal”; response options for the
HRQOL subscales are also on a five-point Likert-type scale and
range from “none of the time” to “all of the time.” The symptom
severity subscale and the HRQOL subscale scores are inverse.
Higher symptom scores indicate greater symptom severity, while
higher HRQOL subscale scores indicate better HRQOL. The UFS-
QOL questionnaire has demonstrated strong reliability, validity,
and responsiveness [9,12].
Uterine fibroid symptom and quality of life-hysterectomy
questionnaire
Because the instructions of the UFS-QOL questionnaire are based
on the presence of uterine fibroids and menstrual periods, the
UFS-QOL questionnaire was modified to become the UFS-QOL-
Hysterectomy questionnaire to allowwomenwith hysterectomies
to respond. As such, the introductory paragraph was changed to
instruct the participant to consider each symptom as it relates
to how she feels “after your hysterectomy” as opposed to related toher symptoms from “uterine fibroids ormenstrual cycle during the
previous 3 months.” Otherwise the questions, response options,
and scoring are identical to those of the original UFS-QOL ques-
tionnaire.
Statistical analysis
Scoring of the questionnaires was performed according to the de-
velopers’ guidelines. Analyses were performed by using SAS ver-
sion 9.1.3; all statistical tests were identified a priori, and no data
imputations were performed for missing data. All statistical tests
were two-tailed and were conducted with type I error probability
fixed at 0.05.
Descriptive analyses (mean and SD) were performed on so-
ciodemographic and clinical characteristics. Spearman correla-
tion coefficients between UFS-QOL questionnaire subscales and
the SF-36 subscales were calculated at each time point. Internal
consistency reliability (Cronbach’s alpha) was calculated at base-
line, 6 months, and 1 year for each UFS-QOL questionnaire sub-
scale and total score for each treatment group and for each UFS-
QOL-Hysterectomy subscale and total score at 6 months and 1
year. UFS-QOL questionnaire scores were compared across the
three treatment groups at baseline, 6 months, and 1 year by using
general linearmodels. Pairwise comparisons betweenmeanswere
performed by using Scheffe’s test adjusting for multiple compari-
sons in the models. To determine the responsiveness of the UFS-
QOL-Hysterectomy questionnaire change scores, effect sizes from
baseline to the 1-year visit were calculated by treatment group.
Effect size was interpreted as small (0.20), moderate (0.50), or large
(0.80) following the guidelines proposed by Cohen [13].
Results
Participants
A total of 274womenwhowere scheduled to undergo fibroid treat-
ment were enrolled into the study and completed the baseline
packet. Of these, 107 underwent UFE, 61 underwentmyomectomy,
and 106 underwent hysterectomy. There were 89 (83%), 55 (90%)
and 91 (86%) women who completed the 12-month follow-up visit
within these treatment groups, respectively. Detailed description
of the demographic characteristics of participants is described
elsewhere [10]. Briefly, the mean age of the participants across all
three treatment groups was 43.1 4.5 years. Almost all the partic-
ipants were white (44%) or African-American (45%), and 80% were
employed full-time. There were significant differences in several
demographic characteristics among the three fibroid treatment
groups, including age, education, and time since last menstrual
period (Table 1).Women in themyomectomygroupwere theyoung-
est (UFE: 43.2 years; myomectomy: 40.6 years; hysterectomy: 44.5
years; P  0.0001), and women who had a hysterectomy were more
likely to have secondary or high school as their highest level of ed-
ucation (P  0.01), while the women in the UFE and myomectomy
groups reported a higher education level. The treatment groups
did not differ significantly in terms of employment status, comor-
bid conditions, height, weight, or body mass index.
UFS-QOL-Hysterectomy questionnaire internal consistency
reliability
Cronbach’s alphas were calculated for each UFS-QOL-Hysterec-
tomy questionnaire subscale to assess internal consistency reli-
ability. The UFS-QOL-Hysterectomy questionnaire demonstrated
good internal consistency reliability at the 6-month follow-up
(range: 0.70 for self-consciousness to 0.96 for three subscales) and
1-year follow-up visits (range: 0.66 for symptom severity to 0.95 for
HRQOL total) (Table 2).
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The correlations between the UFS-QOL-Hysterectomy question-
naire subscale scores and total score and the SF-36 subscale
scores were in the expected directions andmagnitudes with the
associated subscales. The hypothesized strong correlations
were moderate to large, indicating good concurrent validity.
Similar patterns of correlations were observed across the three
treatment groups. Correlations among all UFS-QOL-Hysterec-
tomy questionnaire HRQOL subscales and the SF-36 at 6 months
ranged from 0.00 (concern-vitality; UFE group) to 0.70 (energy/
mood-vitality; myomectomy group) across the treatment
groups. At 12 months, the correlations ranged from 0.03 (self-
consciousness-general health; hysterectomy group) to 0.70 (en-
ergy/mood-vitality; hysterectomy group) across the treatment
groups. As the UFS-QOL-Hysterectomy questionnaire symptom
severity subscale is inverse to the SF-36 subscales, the correla-
Table 1 – Baseline demographic characteristics, by fibroid t
Characteristic U
(n 
Age (y), mean  SD 43.2
Race, n (% yes)
White 40 (
Black 57 (
Asian 2 (
Hispanic 3 (
Other† 4 (
Missing 1 (
Employment status, n (% yes)
Employed, full time 93 (
Employed, part time 3 (
Homemaker 6 (
Student 0 (
Unemployed 3 (
Disabled 2 (
Highest level of education, n (% yes)
Elementary/primary school 0 (
Secondary/high school 8 (
Some college 29 (
College degree 35 (
Postgraduate degree 35 (
Comorbid medical conditions,† n (% yes)
None 52 (
Arthritis 6 (
Asthma 9 (
Cancer 2 (
Chronic obstructive pulmonary disease/emphysema 2 (
Diabetes 3 (
Heart problems 0 (
Hypertension 19 (
Other‡ 24 (
Height (ft), mean  SD 5.4
Weight (lb), mean  SD 169.5
Body mass index, mean  SD 28.4
Time since last menstrual period (d), mean  SD 14.5
UFE, uterine fibroid embolization.
* P values from t test for continuous variables and chi-square for cat
† Not mutually exclusive.
‡ Other includes Addison’s disease, allergies, anemia, anorexia, an
fatigue syndrome, Crohn’s disease, epilepsy, eczema, gastroesopha
roidism, hypothyroidism, lupus,mitral valve prolapse,major depre
disorder, osteoporosis, polycystic kidney disease, pulmonary hyan
sleep apnea, and spinal/neck degeneration.tions were negatively and moderately correlated with the SF-36bodily pain subscale, physical functioning subscale, and physi-
cal component summary score at both 6 and 12 months (r 
0.29 to r  0.49; all P  0.05).
UFS-QOL-Hysterectomy questionnaire responsiveness
There were significant improvements from baseline to 1 year on
all UFS-QOL-Hysterectomyquestionnaire subscales,with absolute
change scores ranging from 37.6 (sexual function) to 66.3 (concern)
(Table 3). Effect sizes ranged from 1.23 (sexual function) to 2.55
(symptom severity), indicating that the UFS-QOL-Hysterectomy
questionnaire is responsive to treatment.
Outcomes of fibroid treatment
Because the UFS-QOL-Hysterectomy questionnaire is valid, re-
ment.
)
Myomectomy
(n  61)
Hysterectomy
(n  106)
P*
40.6  5.6 44.5  3.9 0.0001
28 (45.9) 52 (49.1) 0.6553
26 (42.6) 39 (36.8)
2 (3.3) 3 (2.8)
3 (4.9) 5 (4.7)
2 (3.3) 4 (3.8)
0 (0.0) 3 (2.8)
51 (83.6) 73 (68.9) 0.0817
4 (6.6) 13 (12.3)
1 (1.6) 11 (10.4)
0 (0.0) 1 (0.9)
2 (3.3) 4 (3.8)
3 (4.9) 4 (3.8)
0 (0.0) 1 (0.9) 0.0114
5 (8.2) 23 (21.7)
17 (27.9) 33 (31.1)
23 (37.7) 34 (32.1)
16 (26.2) 15 (14.2)
34 (55.7) 47 (44.3) 0.3653
8 (13.1) 9 (8.5) 0.2406
5 (8.2) 10 (9.4) 0.9509
0 (0.0) 0 (0.0) 0.2076
0 (0.0) 1 (1.0) 0.5246
1 (1.6) 2 (1.9) 0.8521
1 (1.6) 2 (1.9) 0.3743
10 (16.4) 18 (17.0) 0.9731
11 (18.0) 29 (27.4) 0.3743
5.4  0.2 5.4  0.2 0.8656
.4 163.1  42.7 171.5  46.6 0.4941
27.2  6.7 28.5  7.4 0.4691
.2 31.7  54.6 46.9  107.3 0.0072
cal variables.
back problems, breast cancer, bulimia, cervical dysplasia, chronic
reflux disease, hepatitis C, high cholesterol, hypertension, hyperthy-
, Meneire’s disease,migraines,muscle tension, obsessive compulsive
g granulomas, recent foot and hand surgery, rheumatoid arthritis,reat
FE
107
 3.7
37.4)
53.3)
1.9)
2.8)
3.7)
0.9)
86.9)
2.8)
5.6)
0.0)
2.8)
1.9)
0.0)
7.5)
27.1)
32.7)
32.7)
48.6)
5.6)
8.4)
1.9)
1.9)
2.8)
0.0)
17.8)
22.4)
 0.2
 43
 6.5
 16
egori
xiety,
geal
ssion
ilizinliable, and responsive to treatment, scores on the UFS-QOL and
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the three fibroid treatment groups at 1 year. Women who had
undergone hysterectomy had significantly better scores (P 
0.01) on the symptom severity, concern, activities, and HRQOL
total subscales than did women who had undergone UFE or
myomectomy (Fig. 1). Women who had undergone hysterec-
tomy also had significantly better (P  0.05) energy/mood and
ontrol scores than did women who had undergone myomec-
omy and had significantly better (P  0.05) self-consciousness
cores than did women who had undergone UFE. There was no
ignificant difference on any SF-36 subscale score across the
hree treatment groups at 6 months or 1 year except for bodily
ain at 6 months for which women who had undergone UFE
eported lower (worse) scores than did those who had under-
one hysterectomy (P  0.05).
Table 2 – Internal consistency reliability (Cronbach’s alpha
posthysterectomy.
UFS-QOL-Hysterectomy
questionnaire*
Number of
items (k)
6 m
UFE
(n  94)
Myomecto
(n  55
Symptom severity 8 0.78 0.91
Concern 5 0.95 0.98
Activities 7 0.95 0.97
Energy/mood 7 0.94 0.97
Control 5 0.88 0.96
Self-consciousness 3 0.81 0.89
Sexual function 2 0.96 0.97
HRQOL total 29 0.97 0.99
HRQOL, health-related quality of life; UFE, uterine fibroid emboliza
Life-Hysterectomy.
* Women who had undergone hysterectomy completed the UFS-QO
† The alpha could not be calculated for the concern subscale at 1 y bec
of the time” for three of the five items).
Table 3 – Responsiveness of the UFS-QOL-Hysterectomy
questionnaire, baseline to 1 y.
UFS-QOL-Hysterectomy
questionnaire subscale
Mean change
score*
P† Effect
size‡
Symptom severity§ 56.8 0.0001 2.55
Concern 66.3 0.0001 2.28
Activities 53.2 0.0001 1.95
Energy/mood 44.6 0.0001 1.69
Control 47.9 0.0001 1.83
Self-consciousness 48.1 0.0001 1.62
Sexual function 37.6 0.0001 1.23
HRQOL total 51.0 0.0001 2.16
HRQOL, health-related quality of life; UFS-QOL-Hysterectomy,
Uterine Fibroid Symptom and Quality of Life-Hysterectomy.
* Calculated as 1-y visit score minus baseline score; scores range
from 100 to 100.
† Paired t tests comparing responses at baseline and 1 y.
‡ Calculated as score difference  SD of baseline score.
§ Scores range from 0 to 100; higher scores indicate greater symp-
tom severity.
 Scores range from 0 to 100; higher scores indicate better HRQOL.Discussion
The UFS-QOL questionnaire, a valid and reliable measure of fi-
broid-related symptoms and HRQOL impact, was modified to be
applicable to women posthysterectomy (UFS-QOL-Hysterectomy
questionnaire) andwas utilized for the first time in this study. The
UFS-QOL questionnaire and theUFS-QOL-Hysterectomyquestion-
naire demonstrated acceptable internal consistency reliability
and responsiveness to treatment, indicating that they are both
valid and reliable patient-reported outcomes (PROs) of symptoms
and HRQOL.
In CER, the generation and synthesis of evidence that com-
pares alternative methods of treatment [14] is vital to the future
of medicine and patient care. The Patient Protection and Afford-
able Care Act, passed in 2010, mandates that CER be conducted
to evaluate and compare “health outcomes and the clinical ef-
fectiveness, risks, and benefits of two or more medical treat-
ments, services, and items.” PROs are particularly important for
a symptom-based condition such as uterine fibroids. An im-
provement in HRQOL or reduction in symptoms may be just as
essential in evaluating treatment as a clinical outcome such as
reduction in fibroid size. When patients are involved in their
own care as active contributors in their health care decisions
and care [15], their participation may result in favorable out-
comes [16]. Having evidence of treatment outcomes that is un-
derstandable to patients is crucial to allow them to be involved
in the decision making and to make informed decisions in their
care and treatment.
To compare the outcomes of multiple treatments, the PRO
measure must be applicable across all treatments. Generic PRO
measures are meant to be just that—generic so that they can
apply across a range of diseases and can be used across patient
populations. These measures, however, may not have the abil-
ity to detect important change in a particular condition or to
assess important aspects of a condition. Disease-specific PRO
measures focus on the important aspects of a condition and
therefore are more responsive to treatment and change [17].
The specificity inherent in a disease-specific PRO, however, may
limit its applicability across treatments, as was the case for the
UFS-QOL questionnaire. Although the measure is a uterine fi-
broid–specific PRO measure, its appropriateness was limited for
CER because it was not applicable across uterus-sparing and
he UFS-QOL-Hysterectomy questionnaire at 6 mo and 1 y
Cronbach’s alpha
1 y
Hysterectomy*
(n  95)
UFE
(n  89)
Myomectomy
(n  55)
Hysterectomy*
(n  91)
0.85 0.83 0.85 0.66
0.96 0.95 0.97 n/a†
0.91 0.97 0.96 0.88
0.94 0.93 0.97 0.92
0.90 0.93 0.94 0.92
0.70 0.87 0.89 0.71
0.96 0.95 0.94 0.92
0.96 0.98 0.98 0.95
UFS-QOL-Hysterectomy, Uterine Fibroid Symptom and Quality of
terectomy questionnaire at the 6-mo and 1-y follow-ups.
of no variability in the subscale scores (all respondentsmarked “none) of t
o
my
)
tion;
L-Hys
auseuterus-removing treatments. A simple change in the measure’s
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ble to women posthysterectomy (UFS-QOL-Hysterectomy ques-
tionnaire) while remaining comparable to the original UFS-QOL
questionnaire. Thus, the UFS-QOL questionnaire and the UFS-
QOL-Hysterectomy questionnaire allowed comparison of out-
comes of various uterine fibroid treatments in this study.
The modification of a psychometrically sound PRO measure
should not be undertaken lightly, especially when the goal is to
be able to use the scores on a modified version in comparison to
the scores on the original version. It is important that the mod-
ifications be logical and minimal and that the psychometric
characteristics of the modified version be assessed in a similar
patient population as the original version. With these caveats in
mind, this PRO modification approach can be used in other con-
ditions and disease areas and will greatly enhance the conduct
of CER and enable patients to make informed health care deci-
sions.
A limitation to this study is the lack of random assignment to
treatment group, because participants were enrolled after their
treatment was selected. The myomectomy treatment group was
slightly smaller than the UFE and hysterectomy groups, reflecting
the lower prevalence of this treatment. The UFS-QOL question-
naire performed well in this group, even with the smaller sample
size. Further research could be conducted to substantiate the find-
ings of this study.
The UFS-QOL questionnaire and the UFS-QOL-Hysterectomy
Fig. 1 – UFS-QOL/UFS-QOL-hysterecquestionnaire are valid and reliable PRO measures of symptomsand HRQOL and should be used in future studies evaluating the
effectiveness of treatments for uterine fibroids.
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grant from the US Army (USAMRAA Award #W81AWH-05-2-005,
Gynecologic Disease Program).
R E F E R E N C E S
[1] Cramer SF, Patel A. The frequency of uterine leiomyomas. Am J Clin
Pathol 1990;94:435–8.
[2] Day Baird D, Dunson DB, Hill MC, et al. High cumulative incidence of
uterine leiomyoma in black and white women: ultrasound evidence.
Am J Obstet Gynecol 2003;188:100–7.
[3] Stovall DW. Alternatives to hysterectomy: focus on global endometrial
ablation, uterine fibroid embolization, and magnetic resonance-guided
focused ultrasound. Menopause 2011;18:443–50.
[4] U.S. Government. Patient Protection and Affordable Care Act (PPACA).
In: 111th United States Congress, ed., Public Law 111–148. Washington,
DC, 2010.
[5] Dilek S, Ertunc D, Tok EC, et al. The effect of myomectomy on health-
related quality of life of women with myoma uteri. J Obstet Gynaecol
Res 2010;36:364–9.
[6] Edwards RD, Moss JG, Lumsden MA, et al. Uterine-artery embolization
versus surgery for symptomatic uterine fibroids. N Engl J Med 2007;
356:360–70.
[7] Eisinger SH, Fiscella J, Bonfiglio T, et al. Open-label study of ultra low-
scores at one year, by treatment.1tomydose mifepristone for the treatment of uterine leiomyomata. Eur J
Obstet Gynecol Reprod Biol 2009;146:215–8.
[[
[
[
[
[
679V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 6 7 4 – 6 7 9[8] Moss J, Cooper K, KhaundA, et al. Randomised comparison of uterine artery
embolisation (UAE)with surgical treatment in patientswith symptomatic
uterine fibroids (REST trial): 5-year results. BJOG 2011;118:936–44.
[9] Spies JB, Coyne K, Guaou Guaou N, et al. The UFS-QOL, a new disease-
specific symptom and health-related quality of life questionnaire for
leiomyomata. Obstet Gynecol 2002;99:290–300.
[10] Spies JB, Bradley LD, Guido R, et al. Outcomes from leiomyoma therapies:
comparisonwith normal controls. Obstet Gynecol 2010;116:641–52.
11] Ware JE, Snow KK, Kosinski M, et al. SF-36 Health Survey Manual and
Interpretation Guide. Boston, MA: New England Medical Center, The
Health Institute, 1993.
12] Harding G, Coyne KS, Thompson CL, et al. The responsiveness of the
uterine fibroid symptom and health-related quality of life
questionnaire (UFS-QOL). Health Qual Life Outcomes 2008;6:99.
[13] Cohen J. Statistical Power Analysis for the Behavioral Sciences (2nd
ed.). Hillsdale, NJ: Erlbaum, 1988.
14] Institute of Medicine. Initial National Priorities for Comparative
Effectiveness Research. Washington, DC: The National Academies
Press, 2009.
15] Kiesler DJ, Auerbach SM. Optimal matches of patient preferences
for information, decision-making and interpersonal behavior:
evidence, models and interventions. Patient Educ Couns 2006;61:
319–41.
16] Duncan E, Best C, Hagen S. Shared decision making interventions for
people with mental health conditions. Cochrane Database Syst Rev
2010:CD007297.17] Lydick E, Yawn BP. Clinical Interpretation of Health-Related Quality of
Life Data. New York: Oxford University Press, 1998.
